Legend Biotech Corp (LEGN) stock
LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.11+0.12 (+0.75%)
Close on Nov 17, 2026Market cap $2.98BP/E –Yield –
Legend Biotech cash
Cash and short-term investments held at the end of each period.
Legend Biotech's cash was $672.90M at Jun 30, 2026. For fiscal 2025 it was $901.90M, up 214.6% from the year before. The highest annual figure on record is $1.28B in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $901.90M | +214.6% |
| FY2024 | Dec 31, 2024 | $286.70M | -77.6% |
| FY2023 | Dec 31, 2023 | $1.28B | +62.6% |
| FY2022 | Dec 31, 2022 | $786.00M | +14.1% |
| FY2021 | Dec 31, 2021 | $688.94M | +51.2% |
| FY2020 | Dec 31, 2020 | $455.69M | +446.6% |
| FY2019 | Dec 31, 2019 | $83.36M | -60.3% |
| FY2018 | Dec 31, 2018 | $210.17M | +9836.9% |
| FY2017 | Dec 31, 2017 | $2.12M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $672.90M | +152.5% |
| Q1 FY2026 | Mar 31, 2026 | $646.40M | +46.3% |
| Q4 FY2025 | Dec 31, 2025 | $901.90M | +214.6% |
| Q3 FY2025 | Sep 30, 2025 | $278.89M | -39.3% |
| Q2 FY2025 | Jun 30, 2025 | $266.50M | +32.4% |
| Q1 FY2025 | Mar 31, 2025 | $441.70M | -50.8% |
| Q4 FY2024 | Dec 31, 2024 | $286.70M | -77.6% |
| Q3 FY2024 | Sep 30, 2024 | $459.28M | -52.3% |
| Q2 FY2024 | Jun 30, 2024 | $201.25M | -83.7% |
| Q1 FY2024 | Mar 31, 2024 | $897.57M | +36.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.28B | +62.6% |
| Q3 FY2023 | Sep 30, 2023 | $963.47M | +18.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.23B | +224.7% |
| Q1 FY2023 | Mar 31, 2023 | $660.05M | -4.2% |
| Q4 FY2022 | Dec 31, 2022 | $786.00M | +61.0% |
| Q3 FY2022 | Sep 30, 2022 | $812.73M | +78.4% |
| Q2 FY2022 | Jun 30, 2022 | $379.78M | -32.5% |
| Q4 FY2021 | Dec 31, 2021 | $688.94M | +726.4% |
| Q2 FY2021 | Jun 30, 2021 | $488.22M | +132.3% |
| Q4 FY2020 | Dec 31, 2020 | $455.69M | +21445.6% |
| Q2 FY2020 | Jun 30, 2020 | $562.39M | – |
| Q4 FY2019 | Dec 31, 2019 | $83.36M | – |
| Q4 FY2018 | Dec 31, 2018 | $210.17M | – |
| Q4 FY2017 | Dec 31, 2017 | $2.12M | – |
See a number that looks wrong?